Prof. Armin Gerger provides a review of the BEACON Study.
Prof. Armin Gerger provides a review of the BEACON Study.
Since 2012 Dr Armin Gerger is professor at the Medial University in Graz, Austria. He works as a clinical oncologist and coordinates the Subcentre for Gastrointestinal Neoplasia at the Comprehensive Cancer Centre, Graz. He leads the Pharmacogenetics Research Unit, at the Division of Clinical Oncology of the Medical University of Graz, and the Area “Cancer” of the Centre for Biomarker Research in Medicine (CBmed). Dr Gerger’s research focuses on prognostic and predictive genetic biomarkers in gastrointestinal cancer, which he developed further as a research fellow at the Norris Comprehensive Cancer Centre of the University of Southern California. Dr Gerger’s research activity is mirrored in several papers in high-ranked scientific journals and significant extramural funding.
Check back soon for expert insights on the latest data in oncogene-addicted non-small cell lung cancer
Two perspectives, one aim: A pathologist and a medical oncologist in discussion
Unmet needs, therapy management, and real-world experience